Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Citius Pharmaceuticals Inc. CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:CTXR)

Fundamentals Snapshot (NDAQ:CTXR)

Current News (NDAQ:CTXR)

Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program

PR Newswire 5 days ago

Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting

PR Newswire November 9, 2022

Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022

PR Newswire October 18, 2022

Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022

PR Newswire October 6, 2022

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

PR Newswire September 28, 2022

Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial

PR Newswire September 22, 2022

Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute

PR Newswire September 15, 2022

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PR Newswire September 8, 2022

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PR Newswire September 7, 2022

Opinion & Analysis (NDAQ:CTXR)

No current opinion is available.

Bullboard Posts (NDAQ:CTXR)

new CTXR research report - great read!

https://marketresearchrepository.com/cancer-breakthrough-of-the-decade/?utm_source=mcnalliemoney+&utm_medium=influencer&utm...
BryceCanada - May 3, 2022

Excellent YT analysis on Citius Pharmaceuticals!

https://youtu.be/hRHnqSPnhdU
BryceCanada - May 3, 2022

RE:Grab hold!

I like the speed CTXR is rolling at, especially when the overall market is down. Sure $5-$7 in sight.
Adwari - June 15, 2021

Grab hold!

SP climbing nicely in anticipation of phase 3 results news and of June. Thinking we will see mid $3 range up to news on successful p3...
Doinitmyway - June 15, 2021

New website with deep DD on CTXR đŸ‘‡

New site with Deep DD on CTXR: Frugalnorwegian.com/ctxr - All information on 1 page - Catalyst countdown timer - Several videos to...
FrugalNorwegian - May 12, 2021

$8.00 Target

https://dawsonjames.com/wp-content/uploads/2021/03/CTXR.3.10.21.pdf?inf_contact_key...
Adwari - May 4, 2021